TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06744777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol.
Study: NCT06678594

Intervention type: PROCEDURE
Intervention: Calcium modification
Description: Patients will undergo one or more of the following procedures, subject to the algorithm:~Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy
Study: NCT06677697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,5%
Description: Group B 30 patients recive 0.5% ropivacine
Study: NCT06677762

Intervention type: PROCEDURE
Intervention: Irreversible electroporation
Description: Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.

Intervention type: PROCEDURE
Intervention: Irreversible electroporation
Description: Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.
Study: NCT06678386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50% sugar reduction
Description: Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
Study: NCT06152848

Intervention type: OTHER
Intervention: Data and samples collection
Description: Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples

Intervention type: OTHER
Intervention: Data and samples collection
Description: Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
Study: NCT06744894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
Description: Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.
Study: NCT06744569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
Study: NCT06743724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation treatment
Description: Patients with low score of Maternal Care Rating Scale received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 2 week.
Study: NCT06174480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryostimulation
Description: Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
Study: NCT05194007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frondanol
Description: Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
Study: NCT05717075

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parents Round
Description: The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parents Round
Description: The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
Study: NCT05436418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.
Study: NCT05420467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w × 4 cycles followed by docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m2, d1, q3w × 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Study: NCT05436418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
Study: NCT05420467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2, d1,8,15, q3w× 4 cycles
Study: NCT05196737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
Study: NCT06391372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol cream
Description: 1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
Study: NCT05762653

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
Study: NCT06559228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConnectedNest
Description: Among those receiving ConnectedNest, participants will receive a secure message to register and download ConnectedNest's patient app, EmpowerNest. They will be directed to complete a set of modules at the baseline through ConnectedNest: demographics, SDoH needs (e.g., social support, transportation, housing) and quality-of-life. They will receive basic training on the functionality and services available within the app (e.g., how to indicate a need, connect with community services). They will be directed to use the app to identify and connect with needed social and community services for 90 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The participants assigned to the control arm will be asked to complete a baseline survey with the same information as the ConnectedNest arm, except their survey will be administered through REDCap.
Study: NCT06404762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tSCTG+ CAF
Description: In the tSCTG group, at the distal end of a second maxillary molar, an incision will be made using a double-bladed scalpel (SKU 10-130-05D; Hu-Friedy, Chicago, IL, USA) bucco-palatally, forming a 1,5 mm thick parallel line. Secondary incisions will be made to separate the graft using a 15c blade on the buccal and palatal sides. Later, the graft will be de-epithelialized extra-orally using a blade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pSCTG+ CAF
Description: In pSCTG group; the graft will be harvested through a single-incision approach at the lateral palatal mucosa
Study: NCT06585540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride IV Prevention
Description: Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride IV Treatment
Description: Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Preventative
Description: Patients in this arm will receive placebo (Normal Saline) while under general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
Study: NCT05420467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w × 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w × 6 cycles
Study: NCT06005636

Intervention type: DIAGNOSTIC_TEST
Intervention: Test delirium state
Description: use scale to test whether ischemic stroke patients have post-stroke delirium

Intervention type: DIAGNOSTIC_TEST
Intervention: Test delirium state
Description: use scale to test whether ischemic stroke patients have post-stroke delirium
Study: NCT05505786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal stance width
Description: Normal self-selected stance width when performing squat exercises.
Study: NCT05395572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
Study: NCT05136742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and diet program
Description: It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet program
Description: balanced restricted diet
Study: NCT06346145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Type of surgery assigned by surgeon in consultation with patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care can consist of dietary intervention, physiotherapy or drug treatment in accordance to the care given in the region of Sweden where the patient resides.
Study: NCT04674228

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT01211951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04286295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Lozenge Product
Description: Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
Study: NCT05436418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2
Study: NCT04380233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome
Description: The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
Study: NCT05436418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant
Study: NCT04380233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Study: NCT05562648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques
Description: Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors.
Study: NCT05436418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant
Study: NCT05562648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysical agents
Description: TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord.
Study: NCT05065619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-2766 High dose (3.75 µg)
Description: Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-2766 Low dose
Description: Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)